Establishment Labs to Announce First Quarter 2021 Financial Results on May 5
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is set to announce its financial results for Q1 2021 on May 5, 2021, before market opens. A conference call will follow at 8:30 am ET. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering innovative silicone gel-filled breast implants branded as Motiva Implants®. These implants are available in over 80 countries and produced in compliance with strict quality standards.
- Innovative product portfolio including Motiva Implants® and Divina® 3D Simulation System.
- Motiva Implants® are available in over 80 countries, indicating strong market presence.
- None.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2021 before the market opens on Wednesday, May 5, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.
To participate in the conference call, dial (877) 407-8039 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13718169. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005103/en/
FAQ
When will Establishment Labs announce its Q1 2021 financial results?
What time is the conference call for Establishment Labs' financial results?
What is the ticker symbol for Establishment Labs?
What products does Establishment Labs offer?
